Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases
Chronic respiratory disorders affect millions of people worldwide. Pathophysiological changes to the normal airway wall structure, including changes in the composition and organization of its cellular and molecular constituents, are referred to as airway remodeling. The inadequacy of effective treatment strategies and scarcity of novel therapies available for the treatment and management of chronic respiratory diseases have given rise to a serious impediment in the clinical management of such diseases. The progress made in advanced drug delivery, has offered additional advantages to fight against the emerging complications of airway remodeling. This review aims to address the gaps in current knowledge about airway remodeling, the relationships between remodeling, inflammation, clinical phenotypes and the significance of using novel drug delivery methods.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 14(2022), 4 vom: 02. Feb., Seite 271-288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhanjal, Daljeet Singh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COPD |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 05.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2021-0081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335547354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335547354 | ||
| 003 | DE-627 | ||
| 005 | 20231225230110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2021-0081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335547354 | ||
| 035 | |a (NLM)35019757 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhanjal, Daljeet Singh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 05.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chronic respiratory disorders affect millions of people worldwide. Pathophysiological changes to the normal airway wall structure, including changes in the composition and organization of its cellular and molecular constituents, are referred to as airway remodeling. The inadequacy of effective treatment strategies and scarcity of novel therapies available for the treatment and management of chronic respiratory diseases have given rise to a serious impediment in the clinical management of such diseases. The progress made in advanced drug delivery, has offered additional advantages to fight against the emerging complications of airway remodeling. This review aims to address the gaps in current knowledge about airway remodeling, the relationships between remodeling, inflammation, clinical phenotypes and the significance of using novel drug delivery methods | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a NDDS | |
| 650 | 4 | |a remodeling | |
| 650 | 4 | |a respiratory disorders | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Sharma, Parvarish |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Meenu |e verfasserin |4 aut | |
| 700 | 1 | |a Tambuwala, Murtaza M |e verfasserin |4 aut | |
| 700 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
| 700 | 1 | |a Paudel, Keshav R |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Shakti D |e verfasserin |4 aut | |
| 700 | 1 | |a Hansbro, Philip M |e verfasserin |4 aut | |
| 700 | 1 | |a Chellappan, Dinesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Satija, Saurabh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 14(2022), 4 vom: 02. Feb., Seite 271-288 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:4 |g day:02 |g month:02 |g pages:271-288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2021-0081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 4 |b 02 |c 02 |h 271-288 | ||